Neurotrope, Inc.
DelistedCIK 1513856fmd_1XK9C6Z4VF9WHSR7494B85WEMKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Feb 01, 2010 to Sep 30, 2020, 42 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | – | – | – | 0 | 1 | 2 | 6 | 5 | 5 | 5 |
| Total operating expenses | 0 | (0) | – | 8 | 9 | 9 | 13 | 13 | 11 | 16 |
| Operating income | – | (0) | (0) | – | – | – | – | – | – | – |
| Interest expense | – | – | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | – | (0) | – | – | – | – | – | – | – |
| Income before taxes | (0) | (0) | – | (8) | (9) | (9) | (13) | (13) | (11) | (15) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (8) | (9) | (9) | (13) | (13) | (11) | (15) |
| Net income | (0) | (0) | – | (8) | (9) | (9) | (13) | (13) | (11) | (15) |
| Net income to common shareholders | – | – | – | (9) | (11) | (10) | (13) | – | – | – |